secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0001140361-23-030932
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Pharma stockholders elect four Class I directors and approve say-on-pay
--------------------------------------------------------------------------------

- Four director nominees elected: Momtazee (126.98M for), McCormick (126.13M for), Scott (131.25M for), Valantine (107.39M for); 14.89M broker non-votes.
- Non-binding advisory vote on executive compensation passed with 104.00M for, 29.90M against, 45.6k abstentions.
- Ratification of Deloitte & Touche as auditor for FY2023 approved with 148.80M for, 22.0k against.
- Total shares represented at meeting: 148.84M out of 160.50M outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036123030932/0001140361-23-030932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036123030932/brhc20054672_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-030932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer